![](https://medcitynews.com/wp-content/uploads/sites/7/2021/03/GettyImages-1227710766.jpg)
FDA Says ‘No’ to Novo Nordisk’s Once-Weekly Insulin
Novo Nordisk’s bid to bring diabetes patients a less burdensome dosing regimen has encountered a setback. The FDA turned down the company’s application for icodec, a slow-acting insulin the company designed for once-weekly dosing as an alternative to daily …